A multi-center retrospective, observational study to establish endoscopic staging of autoimmune gastritis

A Multi-Center Retrospective Observational Study on Endoscopic Atrophic Classification and Clinical Stages of Autoimmune Gastritis - MACC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055147

Enrollment

500

Registered

2024-08-05

Start date

2024-08-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune gastritis(AIG)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients receiving proton pump inhibitors (PPIs) or potassium ion-competitive acid blockers (PCAb) : Cases in which PPI or PCAb was administered within the past year (except for cases in which PPI or PCAb was used for a short period of time as Hp eradication therapy at least 3 months prior to the date of endoscopy). 2) Cases in which immunosuppressive agents were administered. 3) Cases in which objective evaluation of endoscopic ROM extent is difficult. 4) Cases in which the patient or his/her representative refuses to participate in the study. 5) Cases in which the principal/participating physicians and the Central Judging Committee determine that the patient is not suitable for this study.

Exclusion criteria

Exclusion criteria: 1) Patients receiving proton pump inhibitors (PPIs) or potassium ion-competitive acid blockers (PCAb) : Cases in which PPI or PCAb was administered within the past year (except for cases in which PPI or PCAb was used for a short period of time as Hp eradication therapy at least 3 months prior to the date of endoscopy) 2) Cases in which immunosuppressive agents were administered 3) Cases in which objective evaluation of endoscopic ROM extent is difficult 4) Cases in which the patient or his/her representative refuses to participate in the study 5) Cases in which the principal/participating physicians and the Central Judging Committee determine that the patient is not suitable for this study.

Design outcomes

Primary

Measure	Time frame
Frequency of complicated gastric neoplastic lesions and concomitant diseases, and severity of laboratory findings in each stage (stage 0, 1, 2, 3) of endoscopic remnant oxyntic mucosa (ROM) in autoimmune gastritis	—

Secondary

Measure	Time frame
Validity of ROM staging according to status of possible concomitant Hp infection	—

Countries

Japan

Contacts

Public ContactNoriko Kakinoki

Kakogawa Central City Hospital Clinical Research and Clinical Trial Center

n-kakinoki@kakohp.jp079-451-5500

Outcome results